Lipigon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Lipigon Pharmaceuticals's earnings have been declining at an average annual rate of -18.6%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 51.1% per year.
Key information
-18.6%
Earnings growth rate
16.4%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 51.1% |
| Return on equity | -42.6% |
| Net Margin | -73.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Lipigon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 16 | -12 | 7 | 0 |
| 30 Sep 23 | 16 | -14 | 7 | 0 |
| 30 Jun 23 | 16 | -16 | 7 | 0 |
| 31 Mar 23 | 0 | -36 | 7 | 0 |
| 31 Dec 22 | 0 | -38 | 6 | 0 |
| 30 Sep 22 | 0 | -43 | 6 | 0 |
| 30 Jun 22 | 1 | -48 | 6 | 0 |
| 31 Mar 22 | 1 | -45 | 6 | 0 |
| 31 Dec 21 | 2 | -41 | 5 | 0 |
| 30 Sep 21 | 3 | -31 | 5 | 0 |
| 30 Jun 21 | 4 | -21 | 5 | 0 |
| 31 Mar 21 | 4 | -12 | 4 | 0 |
| 31 Dec 20 | 4 | -8 | 3 | 0 |
| 31 Dec 19 | 2 | -5 | 1 | 0 |
| 31 Dec 18 | 0 | -4 | 1 | 0 |
Quality Earnings: LPGO is currently unprofitable.
Growing Profit Margin: LPGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LPGO is unprofitable, and losses have increased over the past 5 years at a rate of 18.6% per year.
Accelerating Growth: Unable to compare LPGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LPGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: LPGO has a negative Return on Equity (-42.64%), as it is currently unprofitable.